Breast Cancer Treatment and Diastolic Dysfunction: Should We Worry About Relaxing in Cardio-Oncology?

JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):211-214. doi: 10.1016/j.jcmg.2019.07.022. Epub 2019 Sep 18.

Authors

Paaladinesh Thavendiranathan¹, Oscar Calvillo-Argüelles²

Affiliations

¹ Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address: dinesh.thavendiranathan@uhn.ca.
² Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

PMID: 31542544
DOI: 10.1016/j.jcmg.2019.07.022

No abstract available

Keywords: anthracyclines; cardiotoxicity; cardiotoxicity cascade; diastolic dysfunction; trastuzumab.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anthracyclines
Breast Neoplasms*
Humans
Trastuzumab
Ventricular Function, Left

Substances

Anthracyclines
Trastuzumab

Grants and funding

CIHR/Canada